Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I study (investigator-initiated) on the safety and pharmacokinetics of Bortezomib with combination chemotherapy in pediatric and young adult patients with refractory acute lymphocytic leukemia

Next Previous
Trial Profile

A phase I study (investigator-initiated) on the safety and pharmacokinetics of Bortezomib with combination chemotherapy in pediatric and young adult patients with refractory acute lymphocytic leukemia

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Apr 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Asparaginase; Cyclophosphamide; Cytarabine; Daunorubicin; Hydrocortisone; Methotrexate; Prednisolone; Prednisolone; Vincristine
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms BZM-ALL-1

Most Recent Events

  • 17 Dec 2015 Planned End Date changed from 31 Dec 2015 to 31 Mar 2016 as reported by University Hospital Medical Information Network - Japan record.
  • 07 Apr 2015 Planned End Date changed from 30 Jun 2015 to 31 Dec 2015 as reported by University Hospital Medical Information Network - Japan record.
  • 24 Jan 2015 Status changed from not yet recruiting to recruiting, as reported by University Hospital Medical Information Network - Japan.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top